Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.65) by 35.38 percent. This is a 38.24 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $20.000 million which beat the analyst consensus estimate of $8.571 million by 133.33 percent.